Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies

15 May 2023

Abstract excerpt

Abstract Human monoclonal antibodies (mAbs) that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been isolated from convalescent individuals and developed into therapeutics for SARS-CoV-2 infection. However, therapeutic mAbs for SARS-CoV-2 have been rendered obsolete by the emergence of mAb-resistant virus variants. Here we report the generation of a set of six human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37188812
DOI: 10.1038/s41564-023-01389-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodiesPMID 37188812Read ↗

Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agentsSemantic proximity Read ↗

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitopeSemantic proximity Read ↗

Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variantsSemantic proximity Read ↗

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinSemantic proximity Read ↗

ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus BlockerSemantic proximity Read ↗

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blockerSemantic proximity Read ↗

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activitiesSemantic proximity Read ↗

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecovirusesSemantic proximity Read ↗

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variantsSemantic proximity Read ↗

Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitorsSemantic proximity Read ↗

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variantsSemantic proximity Read ↗

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.